Contribution of Estrogen Receptors to the Strategy of Breast Cancer Treatment
Polychemotherapy and hormonal therapy are currently the major therapeutic modalities in advanced breast cancer. The former is the most effective (≥ 50 percent response rate) but the second is less toxic, with a response rate of about 30%. The recent development of estrogen receptor determination in breast cancer tissue samples has improved the clinician’s ability to use these modalities either separately or together in an optimum manner.
KeywordsBreast Cancer Estrogen Receptor Endocrine Treatment Advanced Breast Cancer Breast Cancer Treatment
Unable to display preview. Download preview PDF.
- Cox, D.R., 1970, The analysis of binary data. Methuen and Co Ltd., London.Google Scholar
- Heuson, J.C., Engelsman, E., Blonk-van der Wijst, J., Maass, H., Drochmans, A., Michel, J., Nowakowski, H., and Gorins, A., 1975, Comparative trial of Nafoxidine and ethinyloestradiol in advanced breast cancer. An E.O.R.T.C. Breast Cancer Cooperative Group Study. Br. Med. J., 2, 711–713.Google Scholar
- Heuson, J.C., Sylvester, R., and Engelsman, E., 1980, Alternating cyclical hormonal cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An E.O.R.T.C. Trial. Europ. J. Cancer, in press.Google Scholar
- Leclercq, G., and Heuson, J.C., 1976, Estrogen receptors in the spectrum of breast cancer. Current problems in Cancer, 1, n° 6, R.C. Hickey ed., Year Book Medical Publishers, Inc. Chicago, pp. 1–34.Google Scholar
- McGuire, W.L., Carbone, P.P., Sears, M.E., and Escher, G.C., 1975, Estrogen receptors in human breast cancer: an overview, in: Estrogen receptors in human breast cancer. McGuire W.L., Carbone P.P. and Vollmer E.P., eds., Raven Press, New York, pp. 1–7.Google Scholar
- Mouridsen, H.T., and Palshof, T., 1980, CMF versus CMF plus Tamoxifen in advanced breast cancer in postmenopausal subjects. Europ. J. Cancer, in press.Google Scholar